The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of September 4, 2020. Notable advancements include:

• Pfizer announced its late-stage COVID-19 vaccine trial may have results as early as October.
• AstraZeneca started phase 3 trials of its COVID-19 vaccine in the United States.
• Gilead Sciences announced remdesivir received expanded Emergency Use Authorization from the FDA, enabling the drug’s use to treat all hospitalized patients with COVID-19.

Recent News:

• GlaxoSmithKline and Sanofi Just Launched the First Trial of Their COVID-19 Vaccine. Why That Matters.
  Barron’s – September 3, 2020
  GlaxoSmithKline and Sanofi announced early Thursday morning that their COVID-19 vaccine was entering a 440-patient Phase 1/2 clinical trial in the U.S.
• Pfizer CEO confirms late-stage COVID-19 vaccine trial may have results in October
  CNBC – September 3, 2020 
  Pfizer could have results from its late-stage COVID-19 vaccine trial as early as October and has already enrolled 23,000 volunteers in the phase three trial that began in late July.
• Novavax COVID-19 vaccine is safe, published results show
  CNN – September 2, 2020 
  Early stage clinical trial results show the COVID-19 vaccine candidate made by Novavax is safe and elicits an immune response, according to a study published Wednesday in The New England Journal of Medicine.
• Steroids Can Be Lifesaving for COVID-19 Patients, Scientists Report
  New York Times – September 2, 2020 
  International clinical trials published on Wednesday confirm the hope that cheap, widely available steroid drugs can help seriously ill patients survive COVID-19.
• COVID-19 Vaccines: What’s Coming and When?
  Wall Street Journal – September 1, 2020
  Some 170 COVID-19 vaccines are in development around the world, according to the World Health Organization, each one promising to protect people from COVID-19 and allow them to go back to work and school.
• AstraZeneca’s COVID-19 vaccine becomes third to begin Phase three trials in the United States
  CNN – September 1, 2020 
  British drugmaker AstraZeneca said Monday it has started Phase 3 trials of its experimental COVID-19 vaccine in the United States, becoming the third company to start late-stage trials of a vaccine to prevent COVID-19.
• Vir, GSK push COVID-19 antibody drug straight into mid-stage tests
  BioPharma Dive – August 31, 2020 
  Vir Biotechnology and GlaxoSmithKline said Monday they have initiated the first human trial of their experimental COVID-19 antibody drug, a Phase 2/3 study aiming to keep the disease from worsening in patients with mild or moderate COVID-19 symptoms.
• Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
  Gilead- August 28, 2020 
  Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) enabling use of the investigational antiviral Veklury® (remdesivir) to treat all hospitalized patients with COVID-19, in addition to the previous authorization for patients hospitalized with severe COVID-19.